Bayer will unveil the latest data from two Phase III trials evaluating elinzanetant versus placebo in the treatment of vasomotor symptoms associated with menopause at the American College of Obstetricians and Gynecology (ACOG), May 17-19 in San Francisco.

Other presentations will focus on new discoveries about intrauterine systems (IUS) and Bayer's menopause product line.
These presentations demonstrate Bayer's long-standing commitment to advancing women's health care as the company strives to expand treatment options for women.

Copyright (c) 2024 CercleFinance.com. All rights reserved.